Cellaria unites scientific thought leaders and innovators from diverse backgrounds who share a passion for empowering the cancer research community—and accelerating the search for a cure. Through strategic collaborations, we work towards changing the landscape of cancer treatment with more personalized therapeutics. As cancer research is ever-changing and ever-evolving, we know we must remain nimble, relentless, and aligned with both the challenges of researchers and the needs of patients.
Meet Our Team
David Deems, CEO
Mr. Deems is a senior executive with a proven ability to commercialize and successfully launch novel technology products for the life sciences and diagnostic markets. During his career, he has developed and launched over 100 new products, in regulated and research markets, and for large public and small venture-backed companies. Most recently, Mr. Deems was the President and CEO of Xceed Molecular (now part of Axela), a Canadian company with a novel gene expression platform used by clinical laboratories for testing novel biomarkers.
He joined Xceed from Predicant Biosciences, an early-stage proteomics company working to identify protein patterns in blood for the early detection of cancer, where he was responsible for managing Predicant’s product and commercial development efforts. Prior to Predicant, David held senior management positions with several companies focused on bringing novel products successfully into the marketplace. He served as Vice President of Product Development at EXACT Sciences; CEO of Union Biometrica prior to that company’s acquisition by Harvard Biosciences; and Vice President at BD Biosciences, a division of Becton, Dickinson and Company. He holds a Bachelor’s Degree from Boston University.
Dr. Elin Agoston, Director of Scientific Development
Dr. Agoston holds a BA in Chemistry from Vassar College and a Ph.D. in Pharmacology and Molecular Sciences from the Johns Hopkins University School of Medicine. She completed her post-doctoral training at Harvard University, Brigham and Women’s Hospital in the Department of Pathology in clinical research and pre-clinical model system development.
Dr. Agoston has dedicated a significant amount of her post-doctoral work to researching and developing methods for the primary culture of tumor tissues, including ovarian, breast, and other cancers. Her work has led to the development of a novel cell culture media that sustains a higher percentage of the original tumor’s genotypic, proteomic and phenotypic characteristics. She continued developing the media into a product while a scientist at Stemgent and her continued research efforts have created the foundation for Cellaria’s product portfolio.
Jake Loewenheim, Director of Business Development
Dmitry Shvartsman, Director of Stem Cell Program
Connect With Us
Learn more about how Cellaria can help transform your research efficacy.